International Journal of Pharmaceutical Investigation logo
Submit
International Journal of Pharmaceutical InvestigationACADEMIC PUBLISHING
Article

Evaluation of Pharmacokinetic Profile of GLP-1 Receptor Agonist Exenatide in Type 2 Diabetes Experimental Model

1★, 1★ Corresponding author

  1. 1Department of Pharmacology and Toxicology, B. R. Nahata College of Pharmacy, Faculty of Pharmacy, Mandsaur University, Mandsaur, Madhya Pradesh, INDIA.

CORRESPONDENCE

Arshad Nehal Jamali

Department of Pharmacology and Toxicology, B. R. Nahata College of Pharmacy, Faculty of Pharmacy, Mandsaur University, Mandsaur, Madhya Pradesh, INDIA.

arshadjamali82@gmail.com

Received: 17-06-2023; Revised: 04-07-2023; Accepted: 20-07-2023.

Volume 13, Issue 4 · pp. 784-788 · 2023 · DOI: 10.5530/ijpi.13.4.097

ABSTRACT

The study's objective was to evaluate Exenatide for treating Type 2 Diabetic Mellitus (T2DM) in an animal model. The safety profile and dose determination for the in vivo antidiabetic study were established through an acute toxicity study conducted by OECD guideline 425. The plasma levels of exenatide were studied using a pharmacokinetic model in rats. After Exenatide were given to the rats, their behavior, biochemical, and hematological characteristics were tested. Animals were administered Streptozotocin (STZ, 60 mg/mL, i/p) to induce diabetes. Blood glucose levels above 250 mg/dL were diagnostic of diabetes in animals. The drug was non-toxic in toxicity investigation. Results showed that administration of drug did not cause any significant change in behavioral, biochemical, or hematological markers. It was revealed that Exenatide significantly lowered blood glucose levels in diabetic animals. The results of the study indicated that Exenatide has the potential to be utilized as an alternative antidiabetic medicine against Type 2 Diabetes.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Jamali, A. N., & Soni, R. (2023). Evaluation of Pharmacokinetic Profile of GLP-1 Receptor Agonist Exenatide in Type 2 Diabetes Experimental Model. International Journal of Pharmaceutical Investigation, 13(4), 784-788. https://doi.org/10.5530/ijpi.13.4.097

    Copyright and licence

    © 2023 Author(s)

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0